Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
08/31/2014
08/31/2013
08/31/2012
08/31/2011
08/31/2010
Revenue
4
3
0
0
0
0
Revenue Growth (YoY)
100%
--
--
--
--
--
Cost of Revenue
3
3
0
--
--
0
Gross Profit
0
0
0
--
--
0
Selling, General & Admin
1
1
0
0
0
0
Research & Development
0
0
--
--
--
--
Operating Expenses
1
1
0
0
0
0
Other Non Operating Income (Expenses)
0
0
0
0
0
0
Pretax Income
-1
-1
0
0
0
0
Income Tax Expense
--
0
0
0
0
0
Net Income
-1
-1
0
0
0
0
Net Income Growth
0%
--
--
--
--
-100%
Shares Outstanding (Diluted)
242.58
102.55
61.86
54.44
47.91
45.64
Shares Change (YoY)
115.99%
66%
14%
14%
5%
41%
EPS (Diluted)
-0.01
-0.01
-0.01
0
0
-0.01
EPS Growth
-53%
28.99%
104%
6%
-70%
-79%
Free Cash Flow
0
0
0
0
0
0
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
0%
0%
0%
--
--
0%
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
-25%
-33.33%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
0
0
0
0
0
0
EBITDA Margin
0%
0%
0%
0%
0%
0%
D&A For EBITDA
0
0
0
0
0
0
EBIT
0
0
0
0
0
0
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
--
0%
0%
0%
0%
0%
Key Stats
Prev.Close
$0.0001
Open
$0
Day's Range
$0 - $0
52 week range
$0 - $0.001
Volume
198.2K
Avg.Volume
35.9K
EPS (TTM)
-0.01
Dividend yield
--
Market Cap
$166.2K
What is OCLG?
Oncologix Tech, Inc. is a medical holding company, which is engaged in the operation and manufacture of medical device products. The company is headquartered in Kentwood, Michigan. The firm has been engaging manufacturers and stakeholders in the industry both in the United States and South Korea to execute agreements with partners, customers, vendors, and manufacturers, reviewing licenses and sublicense agreements with potential licensors, interviewing and hiring employees, and conducting research and due diligence on potential partners, joint-ventures, and acquisitions in the biotech industry. The firm is also seeking additional acquisitions of diagnostic and biotechnology opportunities.
